Ontology highlight
ABSTRACT:
SUBMITTER: Queirolo P
PROVIDER: S-EPMC5844757 | biostudies-literature | 2018 Feb
REPOSITORIES: biostudies-literature
Queirolo Paola P Spagnolo Francesco F Picasso Virginia V Spano Laura L Tanda Enrica E Fontana Valeria V Giorello Laura L Merlo Domenico Franco DF Simeone Ester E Grimaldi Antonio Maria AM Curvietto Marcello M Del Vecchio Michele M Bruzzi Paolo P Ascierto Paolo Antonio PA
Oncotarget 20160713 15
<h4>Background</h4>BRAF inhibitor vemurafenib achieves high response rate and an improvement in survival in patients with BRAF-mutated metastatic melanoma. However, median progression-free survival is only 6.9 months in the phase 3 study. Retrospective analyses suggest that treatment with BRAF inhibitors beyond initial progression might be associated with improved overall survival. We aimed to prospectively investigate the activity of prolonged treatment with vemurafenib and the addition of fote ...[more]